stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Indivior Pharmaceuticals, Inc.

United States · NASDAQ: INDV · Market cap: · P/E: · P/S:

Indivior makes and sells prescription medicines that treat opioid addiction and substance use disorders.

Indivior sells medicines that help people break free from opioid addiction. Its flagship product is Sublocade, a long-acting injection of buprenorphine that is given once a month and steadily releases the drug into the body. Buprenorphine eases withdrawal cravings without producing the same high as heroin or painkillers, so it helps patients stabilize while they rebuild their lives.

Indivior Pharmaceuticals, Inc. (INDV) SUBLOCADE (buprenorphine extended-release injectable): line art illustration of A single SUBLOCADE prefilled syringe with a distinctive clear barrel and amber-tinted extended-release liquid
SUBLOCADE injection
SUBLOCADE is a once-monthly injection given as a shot.

The company's roots go back inside Reckitt Benckiser, the British consumer goods giant, which developed the drug Suboxone as a tablet that dissolves under the tongue. Indivior was spun off as a standalone public company in 2014 and later moved its primary listing to Nasdaq, though it keeps a big presence in the United States, where the opioid crisis has made addiction treatment a large and growing market. The business is simpler than it looks: it collects money from insurers, government health programs like Medicaid, and patients, mostly in America, for drugs that doctors prescribe to keep people in recovery. The big shift in recent years is from tablets to long-acting injections. A monthly shot is harder to misuse than a pill and easier to stick with, and it can earn a higher price. That bet has paid off—Sublocade has become the company's growth engine while older tablet products slowly fade. Indivior also sells Perseris, an injectable for schizophrenia, a small side business that shows it is not a one-drug story.


The risks are real and worth naming. Indivior has spent years tangled in lawsuits from states and insurers who claim it used tactics to block cheaper generic rivals from the market, and it has paid out large settlements. Competition is also heating up: other companies are developing their own long-acting addiction treatments, and any safety scare or patent loss could hit hard. Still, addiction medicine is a field where demand keeps rising and few firms have deep expertise, which gives Indivior a durable perch.

Saved answer · last researched 16 Nov 2026